Antiphospholipid antibodies are associated with APS, but also frequently found in immune thrombocytopenic purpura


Senior Member
Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS)

Antiphospholipid antibodies (APLA) are associated with anti-phospholipid syndrome (APS), a thrombotic disorder, but they are also frequently detected in immune thrombocytopenic purpura (ITP), a bleeding disorder.

In summary, APLA are prevalent in ITP but their profile differs from APS. In APS, antibodies were predominantly against beta2GP1 and 80% had positive Lupus Anticoagulant, while in ITP the APLA reacted most often with the phospholipids without Lupus Anticoagulant. The difference in APLA may result in opposite clinical manifestations in two disorders.

Immune thrombocytopenic purpura (ITP) is a blood disorder characterized by a decrease in the number of platelets in the blood. Platelets are cells in the blood that help stop bleeding. A decrease in platelets can cause easy bruising, bleeding gums, and internal bleeding.

ITP is an autoimmune disease where your white cells mistakenly recognize your body's platelets as foreign and attack them. It can be triggered by a verity of ways (the classic example is a recent upper respiratory infection) but it can also occur due to certain medications or more chronic diseases like: HIV, Hep C, or Lupus, or myelodysplatic disease. These more serious causes should be ruled out before calling it ITP.
Last edited: